We next investigated the effects of SPRY2 on growth under hormone deprivation in LNCaP cells, an AR‐proficient prostate cancer cell line deficient for both SPRY2 and PTEN (Fig EV1K). This evidence concerns the gene PTEN and prostate carcinoma.